Cocrystal Pharma (OTCMKTS:COCP) Stock Price Passes Above 50 Day Moving Average of $2.31

Cocrystal Pharma Inc (OTCMKTS:COCP) shares crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.31 and traded as high as $2.03. Cocrystal Pharma shares last traded at $1.97, with a volume of 5,649 shares traded.

The firm has a 50 day moving average price of $2.31 and a two-hundred day moving average price of $2.48.

Several institutional investors have recently modified their holdings of COCP. Vanguard Group Inc. raised its holdings in shares of Cocrystal Pharma by 4.4% during the second quarter. Vanguard Group Inc. now owns 360,364 shares of the company’s stock worth $847,000 after acquiring an additional 15,336 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Cocrystal Pharma by 15.3% during the second quarter. BlackRock Inc. now owns 35,323 shares of the company’s stock worth $83,000 after acquiring an additional 4,685 shares in the last quarter. Finally, Wasatch Advisors Inc. raised its holdings in shares of Cocrystal Pharma by 5.4% during the second quarter. Wasatch Advisors Inc. now owns 1,152,731 shares of the company’s stock worth $2,709,000 after acquiring an additional 59,235 shares in the last quarter.

About Cocrystal Pharma (OTCMKTS:COCP)

Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

Further Reading: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.